Klaus von Grebmer

Publications and Insights

• New: We have launched OHE Bulletin, a new monthly newsletter
• Insight: Due to the Unprecedented Nature of H.R. 3, the CBO Analysis is Unreliable and Can’t Inform Policymaking
• Insight: OHE is Launching a New Series to Explore the Latest Attempts to Reduce the Cost of US Healthcare
• New: Virtual ISPOR European 2020
• New: OHE Lunchtime Seminar: Personalised Medicine: Is it an oil-rush or oil-spill?
• New: Funding Challenges in the Malaysian Health Care System
• New: OHE at HESG Winter 2020
• New: OHE Presents at Global AMR R&D Hub Board of Members Meeting in Paris
• New: New OHE Research Funding: Improving Labour Productivity in Primary Care
• New: OHE has an Opening for an Industrial Economist
• New: Press Release: Proposed International Price Index Effectively Outsources Pharmaceutical Policy Decisions to Other Countries
• New: Making Outcome-based Payment a Reality in the NHS: Moving to the Next Phase
• New: OHE Lunchtime Seminar: Closing the ‘Know-do’ Gap for Health Systems Reform at the Policy Level
• New: OHE Lunchtime Seminar: How Do We Measure the ‘Value’ in Value-based Care?
• New: OHE Annual Lecture 2019: The Evolution of U.S. Policy Responses to the Opioid Epidemic
• New: OHE at the 2019 International Health Economics Association (iHEA) World Congress
• New: OHE Lunchtime Seminar: Health Years in Total (HYT): A New Health Objective Function for Cost-effectiveness Analysis
• New: Presentations from ISPOR 2019
• New: OHE at the 2019 Health Technology Assessment International (HTAi) Annual Meeting
• New: OHE at the 2019 Spanish Health Economics Association (AES) Conference
• New: Professor Nancy Devlin appointed as OHE Senior Visiting Fellow
• New: OHE Lunchtime Seminar: Incentives for R&D, Competition and Intertemporal Effects of Payment Rules for Cures
• New: OHE at ISPOR 2019
• New: Can We Really Compare and Aggregate Patient-reported Outcomes Between People and Settings?
• New: OHE Lunchtime Seminar: Cascades of Care in Health Policy Analysis and Planning
• New: Recommendations for Making Outcome-based Payments a Reality in the NHS: An Application to Cancer Drugs
• New: Public Preferences for Health Gains and Cures: A Discrete Choice Experiment
• New: OHE Lunchtime Seminar: What Can NHS Trusts do to Reduce Cancer Waiting Times?
• New: Professor Mireia Jofre-Bonet Appointed Vice President and Head of Research
• New: Can a Strong Economic Case Be Made for Investing in the NHS? 25th Annual Lecture Publication
• New: OHE Achievements in 2018
• New: New Publications: Real-World Evidence for Coverage and Formulary Decisions
• New: New NICE Position Statement – 5L Value Set Still ‘On Hold’
• New: EQ-5D-5L Value Set for England Study Team Responds to the EEPRU Review
• New: Presentations from ISPOR Europe 2018
• New: OHE Lunchtime Seminar: Price Regulation of Generics and Drug Shortages
• New: OHE Lunchtime Seminar: Price Regulation of Generics and Drug Shortages
• New: OHE at the ISPOR Summit on New Approaches to Value Assessment: Towards More Informed Pricing in Healthcare October, 2018
• New: Adrian Towse named 2018 Value Assessment Challenge Award Recipient
• New: New Publication: Advanced Therapy Medicinal Products and Health Technology Assessment
• New: OHE Lunchtime Seminars: Steven Pearson and Janel Hanmer
• New: OHE at the EuroQol Plenary Meeting 2018
• New: OHE’s Director of Research, Professor Nancy Devlin, to Take up New Role at the University of Melbourne
• New: Private Provision of Publicly Funded Health Care: The Economics of Ownership
• New: OHE Lunchtime Seminar: The People’s Prescription – Re-imagining Health Innovation to Deliver Public Value
• New: Measuring UK Medicines Expenditure in the Context of the 2014-18 PPRS
• New: The Impact of New Medicines in the NHS: 70 Years of Innovation
• New: Opportunity Costs of New Health Care Technologies: A Research Agenda
• New: Presentations from EuHEA 2018
• New: Incentives, Competition, and Pharmaceutical Innovation in Europe: The Case of Direct Acting Antivirals for Hepatitis C
• New: Presentations from AES and PROMs Summer 2018
• New: OHE’s Paula Lorgelly Elected as HESG Joint National Organiser
• New: How Much Should Society Pay for a New Orphan Drug? A Contribution to this Debate is now Available in a New OHE Research Paper
• New: Presentations from ISPOR and HTAi 2018
• New: Invitation to OHE’s Annual Lecture 2018: Is There an Economic Case for Investing in the NHS? Really?
• New: OHE at EuHEA 2018
• New: OHE Lunchtime Seminar: Is Hypothecation the Way to Raise the Money for the “multi-year” Funding Settlement That the NHS Has Been Promised?
• New: Quality of Life in Long-term Cancer Survivors: Implications for Future Health Technology Assessments in Oncology
• New: OHE at HESG, AES and PROMs Summer 2018
• New: OHE at HTAi 2018
• New: OHE’s Professor Nancy Devlin Elected as ISPOR’s Incoming President
• New: OHE Lunchtime Seminar: How Can We Evaluate the Cost-effectiveness of Health System Strengthening? A Platforms Perspective
• New: OHE at ISPOR 2018
• New: Making Outcome-based Payments a Reality in the NHS: A Research Collaboration between OHE, RAND Europe and King’s College London
• New: Promoting Evidence-based Health Care Policy in Spain: EvaluAES 7th Annual Workshop
• New: Seminar Briefing: The UK Biotech Sector and Brexit
• New: Professor Graham Cookson Appointed OHE Director Designate
• New: New Publications: Optimal Development and Use of Real-World Evidence for Coverage and Formulary Decisions
• New: New Methods for Analysing the Distribution of EQ-5D Observations
• New: Incorporating Quantitative Patient Preference Data into Healthcare Decision Making Processes: Is HTA Falling Behind?
• New: Appraising Ultra-Orphan Drugs: Is Cost-per-QALY Appropriate?
• New: Why are Mortality Rates Rising for Middle-Aged White Non-Hispanic Americans? Could it Happen in Europe? 24th Annual Lecture Publication
• New: Our Contributions to the Economics of Personalised Medicine
• New: Cancer Survivorship Burden
• New: OHE Lunchtime Seminar: Valuing Children’s Health for Economic Evaluation
• New: Comparing Preference-based Outcome Measures for Overactive Bladder: EQ-5D-5L vs OAB-5D
• New: Seminar Briefing: NHS Agency Staffing and the Impact of Recent Interventions
• New: A New Way of Presenting Health States in Valuation Studies
• New: OHE Lunchtime Seminar: Providing Health Care to NHS Patients: How Much Does Ownership Matter?
• New: OHE at HESG Winter 2018
• New: Challenges in Valuing Temporary Health States for Economic Evaluation: A Review of Empirical Applications of the Chained Time Trade-Off Method
• New: Routine Funding in the UK NHS of Medicines Authorised Between 2011 and 2016 via the European Centralised Procedure
• New: Public Health and Economic Implications of the United Kingdom Exiting the EU and the Single Market
• New: Framing Effects and Study Design Considerations in Stated Preference Research
• New: Effect of Religion on the Perception of Health States: A Qualitative Study
• New: OHE’s Deputy Director is Standing for the iHEA Board
• New: OHE at ISPOR’s 20th Annual European Congress in Glasgow
• New: Antimicrobials Resistance: A Call for Multi-disciplinary Action. How Can HTA Help? A Summary of a Symposium held at HTAi Rome 2017
• New: Open Access Week 2017: Open in Order To…
• New: Opportunities for Utilising ‘Real World Data’ in South Korea
• New: OHE is Pleased to Announce the Appointment Two New Economists: Marina Rodes Sanchez and Chris Sampson
• New: What do Pharmaceuticals Really Cost in the Long Run?
• New: OHE at the EuroQol Plenary Meeting 2017
• New: OHE Lunchtime Seminar: The UK Biotech Sector and Brexit: Past Performance and Future Prospects
• New: An Insurance Framework for Funding New Antibiotics
• New: What Determines Health Care Expenditure in High Income Countries?
• New: OHE Lunchtime Seminar: NHS Agency Staffing and the Impact of Recent Interventions
• New: A New Valuation Method: Directly Eliciting Personal Utility Functions
• New: An Update on the EQ-5D-5L Value Set for England
• New: Comparing the EQ-5D-3L and EQ-5D-5L in a Cohort of Cancer Patients: A Research Collaboration between OHE, Curtin University and King’s College London
• New: New OHE Seminar Briefing: Interventions that Encourage High-value Nursing Home Care: Lessons for the UK
• New: OHE at iHEA 2017: Presentations
• New: OHE Lunchtime Seminar: How Cost-Effective are New Cancer Drugs in the U.S.?
• New: OHE Lunchtime Seminar: Management in the NHS
• New: Why do Immigrants Report Lower Life Satisfaction?
• New: OHE at HTAi Rome
• New: Assessing Value, Budget Impact, and Affordability in Asia
• New: OHE at iHEA Boston 2017: Meet the Team
• New: OHE at ISPOR Boston 2017: Presentations and Posters
• New: OHE at the PROMs Research Conference 2017: Presentations and Posters
• New: Postdoctoral Position in The Economics of Life Sciences R&D
• New: Adaptation to Health States: Sick Yet Better Off?
• New: Professor Dame Sally Davies: Ten Years of the NIHR: Achievements and Challenges for the Next Decade
• New: OHE at HTAi 2017: Meet the Team
• New: OHE at the PROMs Research Conference 2017
• New: Assessing the Value of New Antibiotics: Additional Elements of Value for Health Technology Assessment Decisions
• New: OHE is Recruiting for Two Economists
• New: New Publication: ‘Macro’ Evaluation of the NIHR Oxford Biomedical Research Centre
• New: Multi-criteria Decision Analysis (MCDA) to Support Healthcare Decisions: Opportunities, Challenges and Unresolved Questions
• New: Incentives for New Drugs and Vaccines to Tackle Anti-Microbial Resistance
• New: Invitation to OHE’s Annual Lecture 2017: Why are Mortality Rates Rising for Middle-Aged White Non-Hispanic Americans? Could it Happen in Europe?
• New: Is There Societal Support for an End of Life Premium?
• New: HTAi Asia Policy Forum Briefing Papers: Value and Affordability, Transferability, and Delivery of High Quality HTA for Decision Making
• New: Do People of Different Ages Value Health Differently?
• Insight: The Long-term Sustainability of the NHS and Adult Social Care
• New: Promoting Evidence-based Health Care Policy in Spain: 6th Annual Workshop with EvaluAES
• New: OHE is Pleased to Announce the Appointment of a New Economist: David Mott
• New: New Paper in Quality of Life Research – Can Patients’ Self-Reported Pain be Compared and Aggregated in Multi-Country Studies?
• New: How Important are the Differences Between the EQ-5D-5L and EQ-5D-3L Value Sets?
• New: OHE Lunchtime Seminar and Webinar with Professor David Grabowski: Interventions that Encourage High-Value Nursing Home Care: Lessons for the UK
• New: EQ-5D and the EuroQol Group: Past, Present and Future
• New: Important Variations in Access to Orphan Drugs in France, Italy, Germany, Spain and the UK
• New: New Publication: Gene Therapy: Understanding the Science, Assessing the Evidence, and Paying for Value
• New: New Member of the EuroQol Group: OHE’s Dr Yan Feng
• New: New Seminar Briefing: Delivering an Outcomes-based NHS: Creating the Right Conditions
• New: Educational Webinar: Multiple Criteria Decision Analysis for Health Care Decision Making – Emerging Good Practices
• New: Does a Biomedical Research Centre Affect Patient Care in Local Hospitals?
• New: New OHE Consulting Report: Exploring the Assessment and Appraisal of Regenerative Medicines and Cell Therapy Products: Is the NICE Approach Fit for Purpose?
• New: OHE is Pleased to Announce the Appointment of Two New Economists: Margherita Neri and Jimena Ferraro
• New: How Should We Choose the Measure of ‘Average’ Preferences?
• New: The Office of Health Economics Becomes a Registered Charity
• New: Alastair Fischer appointed as Senior Visiting Fellow at OHE
• New: Value and Cancer: Journal of Cancer Policy Special Issue
• New: OHE Lunchtime Seminar with Andrea Manca: Economic Evaluation for Decision-making and the Value of Access to Individual Patient Data
• New: Maynard Matters: A New Publication Covering Alan Maynard’s Contribution to Global Health Economics
• New: New Publication: Assessing Evidence and Access Associated with NICE HTA Decisions Categorised as “Recommended in Line with Clinical Practice”
• New: Comparing the Cancer-Specific EORTC-8D and the Generic EQ-5D-3L
• New: Recently Published: Reports on Policy Options for Formulary Development in Middle-income Countries and A Case Study from Mexico
• New: New OHE Research Paper: Extrapolation from Progression Free Survival to Overall Survival in Oncology
• New: OHE at HESG Winter 2017: Meet the Team
• New: Recently Published: MCDA to Elicit Stakeholders’ Preferences: The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma
• New: New Publication: Important Aspects of Health Not Captured by EQ-5D
• New: OHE Lunchtime Seminar with Martin Chalkley and Jon Sussex: Providing Health Care to NHS Patients: How Much Does Ownership Matter?
• New: New OHE Research Paper: Uncertainty and Risk in HTA Decision Making
• New: Eliciting the Relative Value of Life Extension at the End of Life
• New: Presentations and Posters from ISPOR Europe 2016
• New: OHE is Recruiting an Economist
• New: Health Economic Evaluation throughout the Ages
• New: New Publication: Bibliometric Trends of Health Economic Evaluation in Sub-Saharan Africa
• New: New OHE Research Paper: The Distribution of the EQ-5D-5L Index in Patient Populations
• New: OHE at ISPOR Europe 2016: Risk-sharing, Differential Pricing, the Cancer Drugs Fund, and Patient Reported Outcomes
• New: Invitation to OHE’s 2016 Annual Lecture with Dame Sally Davies: 10 Years of NIHR: Achievements and Challenges for the Next Decade – 7 November 2016
• New: OHE at the EuroQol Plenary Meeting 2016
• New: Contract Theory: Nobel Offerings to Health Economics
• New: OHE is pleased to appoint two Senior Visiting Fellows: Professor David Parkin and Professor Lou Garrison
• New: New Report Published: Improving Efficiency and Resource Allocation in Future Cancer Care
• New: OHE is Recruiting for Two Economists
• New: OHE at Priorities 2016: Valuing Health at the End of Life and MCDA for Priority Setting
• New: New Publication: Four Case Studies to Explore the Added Value of Oxford AHSN
• New: OHE Lunchtime Seminar on 21 September 2016: Health Economic Evaluation throughout the Ages
• New: Two New Publications: ‘New Age Decision Making in HTA’ and ‘How Can HTA in Asia-Pacific Respond to Increased Clinical Uncertainty?’
• New: The Application of Anchoring Vignettes to the EQ-5D-5L: A Possible Solution to Reporting Heterogeneity in PROMs
• New: OHE Lunchtime Seminar: Health Technology Assessment Scientific and Outcomes Advice on Medicinal Drug Development
• New: OHE at EuHEA 2016: Opportunity Costs, Value Based Pricing, Economies of Scope and Quality of Life
• New: OHE Lunchtime Seminar and Webinar on 21 September 2016: Health Economic Evaluation throughout the Ages
• New: OHE at AES 2016: Early Access Schemes, Equity Adjusted QALYs, Multi-indication Pricing and Formulary Development
• New: OHE is Pleased to Host Four MSc Students for 2016
• New: OHE Awarded Funding for Seven Projects by the EuroQol Research Foundation
• New: OHE Workshop: Surrogate Endpoints as Predictors of Overall Survival in Oncology
• New: OHE and ABPI Webinar: New EQ-5D-5L value sets for England and the UK and Implications for HTA
• New: Dr Francois Maignen joins the OHE team as Head of Operational Research and Data Analysis
• New: New OHE Seminar Briefing: Waiting Time Policies in the Health Sector: What Works?
• New: Age, Utilities, and Self-Reported Health: Issues for HTA
• New: OHE at PROMs Conference Sheffield 2016: Presentations and Posters
• New: OHE’s Paula Lorgelly Appointed as a Visiting Professor at King’s College London
• New: The Precautionary Principle in Healthcare
• New: OHE at ISPOR Washington DC (2): EQ-5D and Valuing Health Gains.
• New: OHE at ISPOR Washington DC (1): HTA, Evidence and Pricing
• New: New Publication: EuroQol Protocols for Time Trade-Off Valuation of Health States
• New: What Drives Variations in Relative Effectiveness Across Countries?
• New: OHE Posters at HTAi: Tokyo 2016
• New: OHE Presentations at HTAi: Tokyo 2016
• New: OHE at ISPOR May 2016: Meet the Team
• New: OHE at ISPOR Italy Chapter – Rome: Are Wider Societal Effects Considered in Healthcare Decision-making?
• New: Three seminars forthcoming at OHE
• New: New publication: The current and future burden of late-onset dementia in the UK: estimates and interventions
• New: New OHE Research Paper: A Review of NICE Methods Across Health Technology Assessment Programmes: Differences, Justifications and Implications
• New: New Publication: Opportunity Costs and Local Health Service Spending Decisions – A Qualitative Study from Wales
• New: Just Published: Systematic Review of Utility Weights Used in Economic Evaluations of Vaccines for Paediatric Infectious Diseases
• New: New OHE Consulting Report on Shaping Research Agenda to Estimate Cost-effectiveness Thresholds for Decision Making
• New: OHE Response: The National PROMs Programme Consultation
• New: Spotlight on OHE: Beyond QALYs, Managed Entry Agreements, Business Models for Antibiotics, and the UK Market for Medicines.
• New: Care at the End of Life: An Economic Perspective
• New: OHE Lunchtime Seminar on 19 April 2016: Evidence that challenges decision makers: experiences and examples
• New: New OHE Publications: An EQ-5D-5L Value Set for England
• New: OHE Appoints Principal Health Economist: Dr Alastair Fischer
• New: New Publication: Spillovers between Public and Private Sector Biomedical and Health Research
• New: Recently published: Are Wider Societal Effects Considered in Healthcare Decision-making?
• New: Just Published: OHE Report on Trends in Scottish Medicines Committee Advice Decisions
• New: New Publication: Headroom Approach to Device Development
• New: OHE’s Nancy Devlin appointed as Honorary Professor, University of Sheffield.
• New: New ISPOR Task Force Report on Multiple Criteria Decision Analysis
• New: New Publications: Study Design Considerations in Health State Valuation Research
• Insight: 5 Things You Should Do with EQ-5D Data
• New: From the Antipodes to the Motherland: Reflections on HTA Decision Makers as Budget Takers and Budget Makers
• New: OHE is Recruiting for a Head of Operational Research and Data Analytics
• New: Seminar at Glasgow Caledonian University: Local Health Care Expenditure Plans and Their Opportunity Costs
• New: OHE at the Health Economists’ Study Group (HESG) Meeting, Manchester 2016
• New: Cost-per-QALY in the US and Britain
• New: New OHE Publication: Model of Behaviour within Fuzzy Budget Constraints
• New: New publication: Using Patient Reported Outcomes to Improve Health Care
• New: Just Published: Systematic Review of PRO Use in Paediatric Populations with Vaccine-Preventable Infectious Diseases
• New: OHE at ISOQOL 2015: Valuing Health-Related Quality of Life
• New: Paula Lorgelly Joins the OHE Team as Deputy Director
• New: OHE at ISPOR Europe: Milan 2015
• New: How to Manage Data Governance in an Era of Real World Evidence (RWE): Working Towards a Set of International Standards
• New: Newly Published Analysis: Dementia: the R&D Landscape
• New: OHE Lunchtime Seminar on 14 December 2015: From the Antipodes to the Motherland: Reflections on HTA Decision Makers as Budget Takers and Budget Makers
• New: New OHE Publication Compares 3L and 5L Versions of EQ-5D as Measures of General Population Health
• New: Valuing Health at the End of Life: A Review of the Empirical Literature
• New: Multi-indication Pricing: Pros, Cons and Applicability to the UK
• New: Waiting Time Policies in the Health Sector: What Works?
• New: Just Published: Testing the Feasibility of Obtaining EQ-5D-5L Values in the United Arab Emirates
• New: OHE at ISPOR Latin America: Policy Options for Formulary Development in Middle-income Countries
• New: Government and Charity Funding of Cancer Research: Public Preferences and Choices
• New: Professor Nancy Devlin Appointed to PHIN’s Board of Directors
• New: Future Cases of Dementia among People Born in 2015 & the Dementia Drug Pipeline
• New: LSE-ICL Medical Innovation Forum on 14th October 2015: Assessing Value and Sustainable Financing of Innovative Therapies.
• New: New Publication: Risk-Sharing Agreements Between Pharmaceutical Manufacturers and Payers
• New: OHE Lunchtime Seminar on 6 October 2015 PharmaDiplomacy: A Proposal for a Collaborative, Mutually Acceptable Approach to Drug Pricing
• New: OHE Welcomes Two New Economists: Bernarda Zamora and Patricia Cubi-Molla
• New: Recently Published: Local Health Care Expenditure Plans and their Opportunity Costs
• New: OHE and University of Sheffield to Collaborate on Research to Re-model the UK Value Set (‘MVH’) for EQ-5D
• New: Incorporating Life-cycle Price Modelling into Pharmaceutical Cost-effectiveness Evaluations
• New: OHE Lunchtime Seminar: Waiting Time Policies in the Health Sector: What Works?
• New: Recently Published: Payer Perspectives on Future Acceptability of Comparative Effectiveness and Relative Effectiveness Research
• New: OHE Appoints New Deputy Director: Associate Professor Paula Lorgelly
• New: European Union Pharmaceutical Markets: A Case for Differential Pricing?
• New: Spotlight on OHE: Value Footprint of Oncology Treatments, Treating Obstructive Sleep Apnoea and Sources of Motivation in Health Care Organisations
• New: An Issues Panel: Developing Cost Effectiveness for Decision Making: What can be Learnt from “Value Based Pricing”?
• New: OHE and Peking University of China to Collaborate on Research to Explore the Inconsistent Ordering of Levels of the EQ-5D-5L Value Set
• New: Guest post: The Economics of Elevated Hospital Mortality at Weekends
• New: An Empirical Study of Two Alternative Comparators for Use in Time Trade-Off Studies
• New: Professor Nancy Devlin Elected to ISPOR Board of Directors
• New: Patient-reported outcomes measures (PROMs) in Health Economics – an Overview and Key Developments in the Field
• New: Seminar Briefing: Improving the Fiscal and Political Sustainability of Health Systems through Integrated Population Needs-Based Planning
• New: OHE at HTAi Oslo: A New Drug Development Paradigm, and the Effect of NICE Decisions Abroad
• New: OHE at HTAi Oslo: A New Drug Development Paradigm, a Framework for Developing Formularies in MICs, and the Effect of NICE Decisions Abroad
• New: 2015 OHE Annual Lecture: Regulation, Reimbursement, and Evidence on New Medical Technologies: Experiences and Future Directions in the United States
• New: OHE at ISPOR Philadelphia: Presentations and Posters
• New: PriMHE Lecture: Relative Effectiveness and the Impact on Drug Development
• New: Do Financial Incentives Trump Clinical Guidance? Hip Replacement Treatment in England and Scotland
• New: OHE Lunchtime Seminar on 11 June 2015: The Economics of Elevated Hospital Mortality at Weekends
• New: OHE at ISPOR Philadelphia Part 2: Risk Sharing, Medical Breakthroughs, Early Access and Drug Development Costs
• New: OHE at ISPOR Philadelphia Part 1: MCDA, Utility Functions and Big Data
• New: OHE’s Professor Nancy Devlin and Koonal Shah Join the EuroQol Research Foundation’s Valuation Working Group
• New: international Decision Support Initiative (iDSI): Mapping of Priority-setting in Health in 17 Low and Middle Income Countries Across Asia, Latin America and Africa
• New: OHE Publishes in the Journal of Comparative Effectiveness Research: Future Expectations of Evidence of Relative Effectiveness in Europe and Comparative Effectiveness in the USA in 2020
• New: New Business Models for Antibiotics. What Can We Learn from Other Industries?
• New: Assessing the Use of Multi-indication Medicines: A Review of Current Data Capabilities in the UK
• New: OHE’s Deputy Director Jon Sussex to Become Chief Economist at RAND Europe
• New: OHE is Recruiting for Two Positions: A Deputy Director and an Economist.
• New: OHE Lunchtime Seminar on 29 April 2015: Do Financial Incentives Trump Clinical Guidance? Hip Replacement in England and Scotland
• New: Published in Health Economics: the Effect of Free Personal Care for the Elderly on Informal Caregiving
• New: A Framework for Payer Assessment of the Value of New Technologies: A US Approach
• New: Do Respondents Completing Abstract, Hypothetical Priority-Setting Exercises Agree with the Policy Implications of Their Choices?
• New: OHE Briefing on Incentives to Follow Best Practice in Health Care
• New: OHE Occasional Paper Critiques the Claxton et al. £13,000 per QALY Estimate
• New: Pharmaceutical Pricing in Emerging Markets: Effects of Income, Competition, and Procurement
• New: Medical Research: How Long Does it Take?
• New: Benefiting Sooner from Medical Research
• New: Universal Health Coverage: The Holy Grail? 21st Annual Lecture Publication.
• New: OHE Welcomes Dr. Aslam Anis
• New: OHE Lunchtime Seminar on 23 February 2015: The Impact of Price-cap Regulations on Entry and Exit by Generic Pharmaceutical Firms in Canada
• New: Spotlight on OHE: Opportunity Costs of NICE Decisions in Wales and HESG 2015
• New: Multinational Evidence of the Applicability and Robustness of Discrete Choice Modeling for Deriving EQ-5D-5L Health-State Values
• New: Recently Published: New Report Comparing Usage of Medicines in the UK with Other Countries
• New: OHE Lunchtime Seminar: Improving Sustainability through Needs-Based Planning
• New: Spotlight on OHE: EQ-5D-5L, Next Generation Sequencing, and MCDA
• New: EQ-VAS an Important and Under-used Element of the EQ-5D
• New: OHE in the BMJ: Reforming the Cancer Drug Fund, and Reviving the PROMs Programme
• New: Biosimilar Competition: Lessons from Europe and Prospects for the US
• New: Just Published: Empirical Study Examining Public Preferences Regarding End of Life Treatments
• New: OHE at ISPOR Europe: Presentations
• New: OHE Seminar Launches ‘An EQ-5D-5L Value Set for England’
• New: OHE at ISPOR Europe: Posters
• New: Spotlight on OHE: Adaptive Pathways, Economic Evaluation, Stated Preferences and Life-cycle Price Modelling
• New: OHE at ISPOR Europe 2: Conceptual and Practical Challenges in Judging Value
• New: OHE has an Opening for an Economist
• New: OHE at ISPOR Europe 1: Impact of NICE on Innovation and Value
• New: OHE’s Devlin Co-Author on Prize-Winning EQ-5D Paper
• New: Towse at ISPOR: Macro HTA and Managed Entry Agreements
• New: Spotlight on OHE: Innovation, Regulation and Antibiotics
• New: Cost Savings from Treating Obstructive Sleep Apnoea: OHE Consulting Report
• New: Competition and Outcomes in the NHS: Hip Replacement
• New: Generating EQ-5D-5L Values in the UAE with TTO and DCE: Initial Results
• New: Annual Lecture 2014: Is Universal Health Coverage the Holy Grail?
• New: What Determines the Shape of an EQ-5D Index Distribution?
• New: Bengt Jönsson Honoured for Contribution to Health Economics
• New: Spotlight on OHE: Competition in the NHS, HESG, Publications
• New: Interdependencies in Funding Medical Research in the UK
• New: OHE Consulting Report on the Trajectory of Dementia in the UK
• New: Spotlight on OHE: NICE, Biosimilars, HTA
• New: Implementing NICE Decisions in Wales: Opportunity Costs
• New: OHE’s Adrian Towse to Take Office as ISPOR President
• New: Orphan Drugs Policies: A Suitable Case for Treatment
• New: The Expanding Value Footprint of Oncology Treatments
• New: 2014 Annual Lecture: Is Universal Health Care Coverage the Holy Grail?
• New: Innovation in Oncology: Real Option Value and Path Dependence
• New: How Will Demands for Effectiveness Evidence Change Drug Development?
• New: Biosimilars and HTA: Results of a Roundtable Discussion
• New: Use of Cost-effectiveness Evidence in US Health Care: Seminar Briefing
• New: OHE Models Incentives for Antibiotic Drug Development
• New: Defining the Complementarity of Medical Research Across Sectors in the UK
• New: Using Performance Thresholds to Affect GP Behaviour: Evidence from Scotland
• New: Pricing Variations Within and Across Countries: Gauging Efficiency
• New: Benefiting from the Promise of Personalised Medicine: Recent OHE Presentations
• New: Social Preferences and Burden of Illness in Value-based Assessments
• New: Variations in Outcome and Costs in NHS Hospitals: Recent Report
• New: Contracting for Quality in the NHS: 20th Annual Lecture Publication
• New: OHE at HESG: Value-based Assessment in the UK; Developing the EQ-5D-5L
• New: OHE Welcomes Charlesworth and Mays to its Editorial Board
• New: Personalised Medicine and the Value of Molecular Diagnostics: Case Studies
• New: Inconsistent Use of Cost-effectiveness Thresholds in NHS Scotland
• New: Adjusting Patient Case Mix to Compare PROMs across Providers
• New: Using MCDA to Assess the Value of Treatments for Rare Diseases
• New: OHE Consulting Offers New Services in Patient-Reported Outcomes
• New: Critique of Research Proposing to Lower NICE’s Cost-per-QALY Threshold to £12,936
• New: Mike Herdman Appointed as OHE’s Head of Health Outcomes
• New: NICE Decisions: Cost-effectiveness is the Most Significant Predictor
• New: OHE Study Projecting UK Medicines Expenditure Extended to 2018
• New: Assessing Use of the EQ-VAS in the NHS PROMs Programme
• New: Groundbreaking EQ-5D Project Launched in the United Arab Emirates
• New: Updated: OHE Guide to UK Health and Health Care Statistics
• New: Personalised Medicine: Economic Incentives for Evidence Generation
• New: Seminar Updates Project on Time Lags in Medical Research
• New: Published: OHE Study Projecting UK Medicines Expenditure
• New: Initial Findings from Research on an EQ-5D-5L Value Set for England
• New: Dr Fraser Lewis Joins OHE as Head of Statistics
• New: Third Edition of OHE’s Guide to Health Economic Evaluation Released
• New: ISPOR Task Force Report on Performance-Based Risk-Sharing Arrangements
• New: Special Issue of EJHE Examines Progress on Refinement of the EQ-5D
• New: OHE at iHEA: HTA in Emerging Markets, Personalised Medicine, EQ-5D mapping
• New: What Is the Role of Cost-Effectiveness Evidence in US Health Care?
• New: Measuring the Relationship Between Health and Subjective Well-being
• New: Prof Maynard on Ensuring Quality in the NHS: Annual Lecture
• New: OHE Involved in Developing New AMS Report on Stratified Medicines
• New: Forecasting the Challenges and Economics of Drug Development in 2022
• New: Defining Innovation in Medicines and Transforming it into Value
• New: OHE at HESG: Informal Caregiving and Valuing End-of-Life Care
• New: OHE at AES: Medicines Prices in the UK, Health Inequalities in Costa Rica
• New: Critical Factors Affecting Pharmaceutical R&D and the Availability of New Drugs
• New: OHE’s Devlin on Using the EQ-5D to Measure Patients’ Outcomes
• New: 19th Annual Lecture: What Constitutes Credible Evidence of Effectiveness?
• New: OHE’s Towse on Challenges in Valuing Genomic Medicines
• New: Contracting for Quality in the NHS is the Topic of OHE’s 20th Annual Lecture
• New: Exploring the Link Between Health and Wealth in Government Decision Making
• New: OHE’s Adrian Towse is ISPOR President-Elect for 2013-14
• New: Valuing Orphan Medicines Using Multi-Criteria Decision Analysis
• New: OHE Welcomes Professors Rawlins and Smith to its Policy Board
• New: NICE Decisions: Exploring the Influence of Cost-Effectiveness and Other Factors
• New: OHE’s Towse on Quality Standards in the ‘New’ English NHS
• New: Valuing Co-Dependent Medical Technologies: Improving Methods and Processes
• New: Performance-Based Risk Sharing in Health Care: Current Status
• New: OHE is Recruiting a Head of Health Statistics
• New: Lunchtime Seminar: Capturing Preferences about Treatment at the End of Life
• New: OHE Develops New, Bottom-Up Model for Forecasting UK Medicines Expenditure
• New: OHE Welcomes David Parkin as a Visiting Researcher
• New: OHE Presents at Two Key Workshops on Use of EQ-5D in HTA Across Asia
• New: The Economics of the Market for Medicines: 2013 Review
• New: Realising the Value of Medical Research: Health and Economic Benefits
• Insight: Using Competition with Care: Comment on the Revised Regulations for the NHS
• New: OHE This Week: BioWales 2013, UK Medicines Market and EQ-5D in Asia
• New: OHE has a Fixed-Term Opening for an Economist
• New: Reasons for Discontinuation of R&D Projects: Lead and Follow-on Indications
• New: Does Free Personal Care for the Elderly Reduce Informal Caregiving?
• New: Review of Plans for Refining Patient-Reported Outcomes Measures
• New: In Memoriam: George Teeling Smith, OHE’s First Director
• New: Spotlight on OHE: Understanding Value Based Pricing
• New: New Research: Achieving Efficient Prices for Drugs in a Global Context
• New: EQ-5D Index Clustering: Causes and Implications for Health Care
• New: New OHE Study Compares Decisions by Five HTA Agencies on Oncology Meds
• New: Overview of the OHE Study on the Cost of Drug Development Presented
• New: Changes in Determining Medicines Pricing in France, Germany and the UK
• New: Join OHE on Twitter, LinkedIn and SlideShare
• New: R&D Cost Drivers to be Explained by OHE Expert
• New: New Pilot Study: Capturing Public Preferences about Health Care Priorities
• New: Spotlight on OHE: Making Health Care Choices and Decisions
• New: Best Wishes for the New Year!
• New: Spotlight on OHE: Value Based Pricing and New Technologies
• New: Spotlight on OHE: Measurement and Valuation of Health Using PROMs
• New: New Research by OHE and University of Glasgow on cost of QALYs in Scotland
• New: New Findings: Public Attitudes Towards End-of-Life Treatment in England and Wales
• New: OHE Study on Pharmaceutical R&D Costs Released
• New: New Study of Time Lags in Translating Medical Research into Practice
• New: Value Based Pricing in Sweden: Lessons for Design?
• New: Collected Essays by Tony Culyer on Health Economics
• New: Future UK Medicines Spending: Four Nation Analysis
• New: Tracking Changes in the Causes of Death in England and Wales
• New: Comparing Prescription Medicines Prices in the UK to Prices in Other Countries
• New: Join OHE in a Seminar to Discuss IP, Innovation and the Human Genome
• New: Competition in the NHS: Proceed with Care
• New: Meeting the Challenges of Drug Development in 2022: Summary of OHE’s 50th Anniversary Conference
• New: Advances in Oncology Modelling: Recent Results from POI Research
• New: Spotlight on OHE: Recent Awards, Publications and Presentations
• New: OHE Conference on the Future of Drug Development – Register Now
• New: OHE has an Opening for an Economist
• New: OHE’s 50th Celebration: Publications on Tuberculosis Show Constancy and Change
• New: Register Now for the OHE Conference on Drug Development in 2022
• New: OHE Awarded £457K Grant on Measuring Public Preferences for Health States
• New: OHE Conference on Drug Development in 2022: Update
• New: Spotlight on OHE: Development and Use of Measures of Health Worldwide
• New: Jorge Mestre-Ferrandiz Appointed Director of Consulting at OHE
• New: OHE Models Future UK Medicines Spending for the ABPI
• New: Register Now for the OHE Conference on Drug Development in 2022
• New: Register Now: OHE Lunchtime Seminar on Innovation
• New: Save the Date: Drug Development in 2022, OHE’s 50th Anniversary Conference
• New: Register Now: SMEs as a Source of Innovation – OHE Lunchtime Seminar, 4 July
• New: New OHE Consulting Report Explores the Many Faces of Innovation
• New: Prospective Observational Studies: Whether, When and How to Use
• New: New Seminar Briefing: Is Pharmaceutical R&D Experiencing a Productivity Crisis?
• New: HTAinSite: Recent Changes in the Database of NICE Decisions
• New: NICE’s Social Value Judgments: A Closer Look at Progress
• New: OHE has an Opening for an Economist — Consultancy and Research
• New: Time Trends in NICE HTA Decision Making: Setting the Record Straight
• New: For Your Information: Cookies Opt-In Coming in Late May 2012
• New: Can and Should Value Based Pricing Be Applied to Molecular Diagnostics?
• New: New Research on VBP: Disease Severity and Unmet Need in the UK
• New: The Tougher the Better: The Effect of GP Performance Thresholds in Scotland
• New: New: Assessing the Performance of the EQ-VAS in the NHS PROMS Programme
• New: Join OHE for Its 50th Anniversary Annual Lecture with Sir Michael Rawlins
• New: New: 50 Years of OHE Publications Are Available Online
• New: Overview of the Economics of the Market for Medicines in the UK
• New: Can lessons from valuing health be useful in valuing development aid?
• New: Spotlight on OHE: Valuing Spillovers, End-of-Life Decisions and Hospital Outcomes
• New: Allocating Resources Based on “Happiness” – OHE Lunchtime Seminar
• New: New: Pay-for-Performance for Drugs and Incentives for Innovation
• New: Analysing Hospital Variation at the Level of EQ-5D Dimensions
• New: What is the True Value of Spending on Medical Research?
• New: Join Us in Our 50th Anniversary Celebration!
• New: Report: Competition Can Help the NHS – But Proceed with Care
• New: New OHE Report: Time Trends in NICE HTA Decisions
• New: NICE’s Social Value Judgments about Equity in Health and Health Care
• New: Is It Time to Reconsider the Role of Co-Payments in Europe?
• New: Spotlight on OHE: Assessing Value and Balancing Needs in Health Care
• New: Research Funding and Economic Growth
• New: Website Upgrades Launch Today
• New: Upcoming OHE Seminars: MCDA and R&D Productivity
• New: Antibacterials: Roundtable Addresses the Critical Issues
• New: New: Using Happiness to Value Health
• New: Forecasting the UK Medicines Bill to 2014
• New: Just Released: Health and the Use of Medicines in Wales
• New: The Effect of Pay on Job Satisfaction and Performance in the UK NHS
• New: New Insights into Hospital Efficiency: Linking Costs and Patient Outcomes
• New: Spotlight on OHE: Measuring Preferences, HTA Benchmarking, Value-Based Pricing, and Rationing
• New: Valuing Health at the End of Life: Public Preferences
• New: Join OHE at ISPOR: MCDA, Risk Sharing and Value-Based Pricing
• New: Evidence on Valued Based Pricing and Reimbursement Schemes
• New: OHE in the Spotlight: Summer 2011
• New: HTA and Appropriate Drug Pricing Worldwide
• New: Incentives for R&D for New Antimicrobial Drugs
• New: Recent Statistics on Orphan Approvals in Scotland and England
• New: Pricing in Emerging Markets: Income, Competition and Procurement
• New: New: Operationalising Value Based Pricing
• New: Does Relative Effectiveness Vary Across Europe?
• New: New: Achieving World Class Outcomes in Cancer Treatment
• New: New OHE Guide to UK Health Statistics
• New: Previews of Forthcoming Publications
• New: Join us for the 2011 Annual Lecture
• New: OHE is Seeking Two Economists
• New: News Release: Fighting Superbugs
• New: Workshop on Responding to Value-Based Pricing
• New: Drugs and Vaccines for Developing Countries
• New: Measuring Value with Pharmacoeconomics
• New: OHE is Moving its Offices
• New: QALYs v. Other Criteria in NHS Decisions
• New: Effects of Public and Charitable Research Funding
• New: Incorporating Multiple Criteria in HTA
• New: New: Antimicrobial Drug Incentives
• New: Valuing the National Clinical Assessment Service
• New: Value-Based Pricing: OHE Comments
• New: Two Economists Join OHE
• New: Differential Pricing – A Win-Win Solution?
• New: New: Priority Review Vouchers and Innovation
• New: New OHE Commission on Competition in the NHS
• New: The Spanish Medicines Market Today
• New: Exploring Local NHS Decisions about Investment
• New: Comparing Variants of Lead and Lag Time TTO
• New: The Market for Biosimilars
• New: Economic Evidence and NHS Reforms in England
• New: Update: Value-Based Pricing in the UK
• New: Measuring Value: OHE at ISPOR
• New: Seminar Briefing on Science Policy
• New: Report on Orphan Drugs Released
• New: Australia’s Publicly Funded Vaccines Market
• New: Prof Devlin Elected Chair of EuroQol Group
• New: The UK’s Publicly Funded Vaccines Market
• New: Annual Lecture Publication Now Available
• New: Disease severity and public preferences
• New: The Impact of Science Policy Research
• New: Access to Orphan Drugs in the EU
• New: Biomedical and Health Research Spillovers in the UK
• New: New Antimicrobial Drugs: EU Policy Options
• New: Which English Hospital is Best at Hips?
• New: Costs and Bariatric Surgery in England
• New: OHE Consulting: Local and Global Expertise
• New: Value Based Pricing in the UK
• New: Defining Benefit Through Willingness to Pay
• New: Competition in the NHS: ‘Payment by Results’
• New: Comparing Economic Appraisal Guides in England
• New: Limits to Using QALYs in Cancer
• New: Part 2: 2010 Lecture on US Health Reform
• New: Part 1: 2010 Lecture on US Health Reform
• New: Estimating US Savings from Biosimilars
• New: EU Approval of Biosimilars
• New: Reminder: Willingness-to-Pay Seminar
• New: Biosimilars’ Price Dynamic in Europe
• New: Price Competition and Biosimilars
• New: Biosimilars: Modelling the Evolution of the Market
• New: Reminder: 2010 Lecture on US Health Reform
• New: EuroQol Group to Report Key EQ-5D Advances
• New: Lunchtime Seminar: Willingness-to-Pay
• New: Biosimilars and Data Exclusivity
• New: News Release: Report on Patient Choice in the UK
• New: Reminder: Risk Sharing Master Class
• New: Biosimilars: Issues Overview
• New: 2010 Lecture: US Health Care Reform
• New: The Impact of Biosimilars on Markets
• New: HTAinSite: The NICE Decision Database
• New: Workshop on HTA and Regulatory Review
• New: Risk Sharing & Patient Access Schemes Workshop
• New: OHE’s Mestre-Ferrandiz has new appointment
• New: Time Trade Off and Valuing Quality of Life
• New: Measuring Health Output, Productivity and Equity
• New: OHE Lunchtime Seminar on Pricing
• New: OHE Awarded DH Grant for EQ-5D Research
• New: Evaluating Medical Innovation: The Societal View
• New: Lunchtime Seminar: US Pharma Pricing
• New: Getting the Most out of PROMs
• New: PROMs and Choice in the NHS
• New: How Fair? Competition in the NHS
• Publication: Pharmaceutical Prices: A continental view